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Abstract
Background: Hypertension is associated with impaired glucose tolerance and insulin resistance. Medical treatment
that interferes with various steps in the renin-angiotensin system improves glucose tolerance and insulin resistance.
However, it remains unclear if long-acting calcium channel blockers (CCBs) such as azelnidipine and amlodipine
affect glucose tolerance and insulin resistance in clinical practice.
Methods: Seventeen non-diabetic patients with essential hypertension who had controlled blood pressure levels
using amlodipine (5 mg/day) were enrolled in this study. After randomization, either azelnidipine (16 mg/day) or
amlodipine (5 mg/day) was administered in a crossover design for 12-weeks. At baseline and the end of each CCB
therapy, samples of blood and urine were collected and 75 g oral glucose tolerance test (OGTT) was performed. In
addition, hematopoietic progenitor cells (HPCs) were measured at each point by flow cytometry and endothelial
functions were measured by fingertip pulse amplitude tonometry using EndoPAT.
Results: Although blood pressure levels were identical after each CCB treatment, the heart rate significantly
decreased after azelnidipine administration than that after amlodipine administration (P < 0.005). Compared with
amlodipine administration, azelnidipine significantly decreased levels of glucose and insulin 120 min after the 75 g
OGTT (both P < 0.05). Serum levels of high-sensitivity C-reactive protein (P = 0.067) and interleukin-6 (P = 0.035)
were decreased. Although endothelial functions were not different between the two medication groups, the
number of circulating HPCs was significantly increased after azelnidipine administration (P = 0.016).
Conclusions: These results suggest that azelnidipine treatment may have beneficial effects on glucose tolerance,
insulin sensitivity, the inflammatory state, and number of circulating progenitor cells in non-diabetic patients with
essential hypertension.
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Type 2 diabetes mellitus (DM) and hypertension are
strong risk factors for coronary artery disease (CAD) [1].
In addition, postprandial hyperglycemia and hyperinsuli-
nemia are considered to be risk factors for atherosclerotic
disease [2,3]. Hypertension is associated with impaired
glucose tolerance and insulin resistance, resulting in the
development of DM in hypertensive patients [4,5]. If
hypertension and DM coexist, the risk of cardiovascular
disease increases by 2- to 3-fold [6]. Therefore, medica-
tions for preventing new-onset of DM as well as for treat-
ment of hypertension are important in non-diabetic
patients with hypertension. A recent meta-analysis
demonstrated the association between types of antihyper-
tensive agents and incidence of new-onset of DM [7].
The findings suggested that the association between anti-
hypertensive agents and incident of DM was lowest for
angiotensin-converting-enzyme (ACE) inhibitors and
angiotensin-receptor blockers (ARBs) [7]. However, the
anti-diabetic effect of calcium channel blockers (CCBs) is
unclear.
Azelnidipine, a novel long-acting dihydropyridines-
based CCB, reduces blood pressure without increasing
the heart rate in patients with hypertension [8]. Azelni-
dipine has been reported to exhibit organ-protective
effects, including anti-remodeling after myocardial
infarction [9], renoprotection [10], and retarding athero-
sclerotic plaque progression [11]. In addition, azelnidi-
pine has several unique basic and clinical effects,
including inhibition of tumor necrosis factor (TNF)-a-
induced interleukin (IL)-8 expression in human umbili-
cal vein endothelial cells by blocking the generation of
nicotinamide adenine dinucleotide phosphate oxidase-
mediated reactive oxygen species [12]; reduction in urin-
ary protein secretion and urinary 8-hydroxydeoxyguano-
sine and liver-type fatty acid binding protein (L-FABP)
levels [10]; and reduction in circulating advanced glyca-
tion end-product (AGE) and soluble form of AGE [13].
Recent experimental studies demonstrated that azelnidi-
pine improved glucose intolerance and lowered the risk
of hyperglycemia-induced metabolic disorders in dia-
betic mice [14,15]. However, its effect on glucose toler-
ance and insulin sensitivity in the clinical practice has
not been studied.
We hypothesized that azelnidipine administration
could improve glucose tolerance and insulin levels in
non-diabetic patients with essential hypertension. We
examined the levels of blood glucose and insulin after
the 75 g oral glucose tolerance (OGTT), lipids, inflam-
matory markers, circulating number of progenitor cells,
and endothelial functions after administration of two
CCBs, azelnidipine and amlodipine in a prospective ran-
domized crossover study.
Methods
Subjects
Eighteen non-diabetic patients with essential hyperten-
sion were enrolled in this study. All subjects were admi-
nistered amlodipine 5 mg once daily and had controlled
blood pressure levels according to Guidelines for the
Management of Hypertension set by the Japanese Society
of Hypertension (JSH 2009) [16]. The exclusion criteria
were as follows: secondary hypertension, DM, serum
creatinine levels ≥ 2.0 mg/dL, symptomatic heart failure,
acute cardiovascular diseases 3 months prior to the
examination, history of gastrointestinal surgery, and sys-
temic diseases, such as hepatic disease, collagen disease,
and malignancy. None of the subjects changed their med-
ications or daily dietary habits during the examination
period. Subjects received full verbal and written explana-
tions of the nature and purpose of this study and gave
their written informed consent. The study was approved
by the Ethical Committee of Juntendo University. This
study has been registered in the UMIN Clinical Trials
Registry System as the trial ID UMIN R000006809 and
the abbreviated trial name as AGENT.
Study design
This study was a prospective randomized crossover design
(Figure 1). Randomization was undertaken by a nontreat-
ing physician using a table of random numbers to match
the two groups for age, sex, and glycated hemoglobin
(HbA1c) levels. After randomization, azelnidipine 16 mg
once daily or amlodipine 5 mg once daily was adminis-
tered in a crossover manner each for 12-week.
Blood and Urine Sampling and Measurements
At the beginning of this study and the end of each treat-
ment, a blood sample was taken from an antecubital vein
after 12 h of fasting. Plasma levels of total cholesterol
(TC), triglyceride (TG), high-density lipoprotein choles-
terol (HDL-C), and high-sensitivity C-reactive protein
(hs-CRP) were measured using standard methods. Low-
density lipoprotein cholesterol (LDL-C) levels were
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Figure 1 Study design of this study. OGTT; oral glucose tolerance
test.
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Page 2 of 7calculated using Friedewald’s formula. The value for
HbA1 c (%) was estimated as National Glycohemoglobin
Standardization Program equivalent value (%) calculated
by the formula: HbA1 c (%) = HbA1 c [Japan Diabetic
Society (JDS)] (%) + 0.4%, considering the relational
expression of HbA1 c (JDS) (%) as measured by the pre-
vious Japanese standard substance and measurement
methods [17]. Plasma levels of IL-6 were measured by
chemiluminescent enzyme immunoassay methods. The
standard 75 g OGTT was performed in a fasting state.
Blood samples for the measurement of glucose and insu-
lin were drawn just before glucose administration, as well
as 30, 60 and 120 min later, as previously described [3].
The morning urine sample was collected for urinalysis at
the beginning and the end of each therapy period. Urin-
ary albumin and L-FABP were measured by an immuno-
turbidimetric method and a specific enzyme-linked
immunosorbent assay, respectively [10]. Both urinary
values were expressed as ratios to the urinary creatinine
concentration.
Flow Cytometric Enumeration of Hematopoietic
Progenitor Cells (HPCs)
Circulating number of HPCs were quantified with Pro-
Count Progenitor Cell Enumeration Kit (BD Biosciences,
San Jose, CA, USA) according to manufacturer’s instruc-
tions using a FACS Canto II Flow Cytometer (BD, Frank-
lin Lakes, NJ, USA) [18]. This assay has an inter-assay
coefficient of variation of 7.0%.
Measurement of Reactive Hyperemia by Peripheral
Arterial Tonometry
Endothelial function as determined by reactive hyperemia
in peripheral arteries was measured using fingertip pulse
amplitude tonometry employing an EndoPAT 2000 device
(Itamar Medical Inc., Caesarea, Israel), as previously
described [19]. Briefly, finger probes were placed on the
middle finger of each subject’s hand. After a 5 min base-
line measurement, the blood pressure cuff on the test arm
was inflated to 60 mmHg above the baseline systolic blood
pressure (SBP) or ≥ 2 0 0m m H gf o r5m i n .A f t e r5m i n ,
the cuff was deflated and peripheral arterial tonometry
(PAT) was recorded for further 6 min. The ratio of the
PAT signal after cuff release compared with baseline value
was automatically calculated through a computer algo-
rithm normalizing for the baseline signal and indexed to
the other arm.
Statistical Analysis
Results are represented in the mean values ± SD. Statisti-
cal analyses were performed using SPSS software (Version
17.0, SPSS Japan Inc., Tokyo, Japan). We used two-way
ANOVA to detect any significant differences, which were
later evaluated by post hoc analysis (i.e., Tukey’s test).
Because this is a crossover study, two independent vari-
ables between azelnidipine and amlodipine administration
were needed for analyses. P < 0.05 was considered to be
significant.
Results
Patient characteristics
One patient was newly diagnosed as having DM after the
75 g OGTT. Therefore, analysis was performed on 17 sub-
jects. Table 1 shows baseline patient characteristics. Of the
17 subjects, 11 were men (mean age 56 ± 13 years). Mean
levels of HbA1 c were relatively low in the study subjects
[5.5 ± 0.4% (JDS 5.1 ± 0.3%)].
Blood pressure and heart rate
Table 2 shows the results of blood pressure and heart rate
at baseline and after administration of the two medica-
tions. No significant differences were observed in SBP
(120.2 ± 11.7 vs. 121.3 ± 8.6 mmHg, P = 0.492) and diasto-
lic blood pressure (DPB) (66.8 ± 7.2 vs. 70.1 ± 8.4 mmHg,
P = 0.145) after administration of azelnidipine and amlodi-
pine, respectively. The heart rate after azelnidipine admin-
istration was significantly lower than that after amlodipine
administration (60.5 ± 6.6 vs. 65.1 ± 7.6/min, P = 0.003).
75 g OGTT
Table 3 shows the levels of blood glucose and immunor-
eactive insulin (IRI) after the 75 g OGTT at baseline and
after administration of the two medications. 120-min glu-
cose levels after azelnidipine administration were signifi-
cantly lower than those after amlodipine administration
Table 1 Baseline characteristics of patients
Male/female 11/6
Age, years 56 ± 13
Body mass index, kg/m
2 24.4 ± 4.0
Impaired glucose tolerance (%) 7 (41)
Dyslipidemia (%) 8 (47)
Current smoker (%) 3 (18)
History of CHD (%) 1 (6)
Hemoglobin A1c, % (JDS) 5.5 ± 0.4 (5.1 ± 0.3)
Fasting blood sugar, mg/dL 96 ± 8
Fasting IRI, μIU/mL 6.9 ± 4.2
eGFR, ml/min/1.73 m
2 83.2 ± 18.3
Medications
ACE-inhibitor (%) 1 (6)
ARB (%) 4 (24)
Beta-blocker (%) 1 (6)
Diuretics (%) 0 (0)
Statin (%) 2 (12)
Data are mean ± SD or numbers. CHD; coronary heart disease, JDS; Japan
Diabetes Society, IRI; immunoreactive insulin, eGFR: estimated glomerular
filtration rate; ACE; angiotensin converting enzyme, ARB; angiotensin-receptor
blockers.
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120-min IRI after azelnidipine administration were signif-
icantly lower than those after amlodipine administration
(47.7 ± 36.4 vs. 57.2 ± 37.9 μIU/mL, P = 0.026).
Laboratory data and PAT ratio
Table 4 shows the results of blood laboratory data and
PAT ratio at baseline and after administration of the two
medications. Changes of TC, LDL-C, HDL-C, and HbA1 c
showed no significant differences between each drug
administration group. After azelnidipine administration,
hs-CRP levels tended to be lower (0.36 ± 0.23 vs. 0.74 ±
0.76 mg/L, P = 0.067) and IL-6 levels were significantly
lower (1.44 ± 0.73 vs. 1.81 ± 0.78 pg/L, P = 0.035) than
those after amlodipine administration. Circulating numbers
of HPC after azelnidipine administration were significantly
higher than those after the amlodipine administration
(3.56 ± 1.59 vs. 2.65 ± 1.17/μL, P = 0.016). No significant
differences were observed in estimated glomerular filtration
rate, L-FABP levels, or urinary albumin levels after the
administration of azelnidipine or amlodipine. No signifi-
cant differences in the PAT ratio were observed after
administration of each of the drug. There were no abnorm-
alities in blood chemistry or other clinical parameters dur-
ing this study period. In addition, no adverse events were
observed.
Discussion
The adverse impact of new-onset DM in treated patients
with essential hypertension is well established [6]. It is
well known that renin-angiotensin system-related agents
such as ACE inhibitors and ARBs have potential for pre-
venting new-onset of DM [7,20]. However, the effect of
CCBs on glucose tolerance and insulin sensitivity has
not been clearly elucidated, particularly in the clinical
setting. The present study demonstrated that azelnidi-
pine administration rather than amlodipine administra-
tion significantly ameliorated glucose intolerance and
the inflammatory state in non-diabetic patients with
essential hypertension. In addition, the number of circu-
lating HPCs was significantly higher after azelnidipine
administration than those after amlodipine administra-
tion. This study is, to the best our knowledge, a first
report that demonstrates the beneficial effects of azelni-
dipine on glucose tolerance and insulin sensitivity in
non-diabetic patients with essential hypertension.
The reason why azelnidipine ameliorated glucose tol-
erance and insulin response in non-diabetic patients
with essential hypertension should be discussed. Recent
studies have clearly demonstrated that inflammation and
oxidative stress play an important role in the pathogen-
esis of hypertension and/or DM as well as atherosclero-
sis [21-24]. Activated proinflammatory cytokines and
increased oxidative stress elicit damage to various
organs. Indeed, increased concentrations of proinflam-
matory cytokines induce a shift toward impaired glucose
tolerance [23,25]. In the present study, circulating levels
of IL-6 and hs-CRP were lower after azelnidipine
administration than those after amlodipine administra-
tion. A previous study also demonstrated that azelnidi-
pine significantly decreased plasma levels of monocyte
chemoattractant protein-1, IL-6, hsCRP, TNF-a,8 - e p i -
prostaglandin F2a, and 8-hydroxydeoxyguanosine in
patients with diabetic nephropathy [22]. Azelnidipine
has been shown to prevent TNF-induced activation of
endothelial cells and IL-8 expression via its antioxidative
properties [12,26]. A recent study showed that azelnidi-
pine even at a non-hypotensive dose improved glucose
tolerance and superoxide production in the skeletal
muscle of diabetic mice [14]. Although direct evidence
regarding oxidative stress is not available in the present
study, the anti-inflammatory effect of azelnidipine may,
at least in part, contribute to the improvement of glu-
cose tolerance. However, in the subjects of upper med-
ian L-FABP/U-Cr values at baseline, the levels of L-
FABP/U-Cr after azelnidipine administration were sig-
nificantly lower than those after amlodipine administra-
tion (data not shown). A recent study reported no
significant changes in fasting glucose levels after azelni-
dipine administration [13]. Indeed, fasting blood glucose
and HbA1 c levels did not show significant changes
even after azelnidipine administration in the present
study. However, 120-min glucose and insulin levels after
azelnidipine administration were significantly lower than
Table 2 Comparison of blood pressure and heart rate
between treatment with azelnidipine and amlodipine
Baseline Azelnidipine
N=1 7
Amlodipine
N=1 7
P **
SBP (mmHg) 119.9 ± 11.5 120.2 ± 11.7 121.3 ± 8.6 0.492
DBP (mmHg) 71.6 ± 10.6 66.8 ± 7.2 70.1 ± 8.4 0.145
Heart rate 64.9 ± 5.9 60.5 ± 6.6* 65.1 ± 7.6 0.003
Data are mean ± SD. SBP; systolic blood pressure, DPB; diastolic blood
pressure. * P < 0.005 vs. baseline. ** azelnidipine vs. amlodipine.
Table 3 Comparison of 75 g oral glucose tolerance test
between treatment with azelnidipine and amlodipine
Baseline Azelnidipine
N=1 7
Amlodipine
N=1 7
P **
Glucose 0, mg/dL 96 ± 8 94 ± 7 94 ± 8 0.826
Glucose 30, mg/dL 174 ± 28 162 ± 34 172 ± 25 0.160
Glucose 60, mg/dL 172 ± 37 181 ± 48 171 ± 41 0.221
Glucose 120, mg/dL 137 ± 30 130 ± 36 149 ± 30 0.039
IRI 0, μIU/mL 6.9 ± 4.2 7.0 ± 3.0 7.0 ± 3.5 0.957
IRI 30, μIU/mL 39.7 ± 16.9 39.8 ± 21.1 42.4 ± 20.8 0.660
IRI 60, μIU/mL 55.9 ± 29.8 56.1 ± 26.4 51.8 ± 27.3 0.465
IRI 120, μIU/mL 44.0 ± 26.8 47.7 ± 36.4 57.2 ± 37.9 0.026
Data are mean ± SD. IRI; immunoreactive insulin. ** azelnidipine vs.
amlodipine.
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small changes in glucose and insulin metabolism, 75 g
OGTT must be performed. Another possibility is inhibi-
tion of the sympathetic nervous system by azelnidipine
treatment. Increased heart rate is a sign of the increased
sympathetic activity [27]. Increased heart rate is asso-
ciated not only with multiple coronary risk factors, but
also morbidity and mortality of cardiovascular diseases
[27]. Indeed, enhanced sympathetic tone could cause
insulin resistance by b-adrenergic stimulation [27]. It
has been reported that dihydropiridine CCBs, even third
generation CCB, such as amlodipine, increase plasma
norepinephrine levels and the ambulatory heart rate
[28]. However, azelnidipine has been reported to prevent
an increase in heart rate by inhibition of the sympathetic
nerve center, rostral ventrolateral medulla [29]. After
azelnidipine administration, the heart rate was signifi-
cantly reduced and was significantly lower than that
after amlodipine administration in the present study.
Therefore, the anti-sympathetic nervous system effect of
azelnidipine may contribute to a favorable effect on glu-
cose tolerance.
Several studies have reported decreased numbers of
circulating progenitor cells such as endothelial progenitor
cells (EPCs) and HPCs in patients with CAD as well as in
patients at high-risk of cardiovascular diseases [21,30]. In
the present study, the number of circulating HPCs after
azelnidipine administration was significantly higher than
after amlodipine administration. Most previous studies
investigated the number of EPCs with respect to athero-
sclerotic disorders. However, a recent study reported that
the numbers of HPCs, rather than EPCs, were associated
with endothelial dysfunction as assessed by an intracor-
onary acetylcholine challenge test [21]. Unfortunately, no
internationally standardized set of criteria for EPC defini-
tion have yet been established. On the contrary, circulat-
ing HPCs are defined as CD34
+ and CD45
dim cells by the
International Society of Hematotherapy and Graft Engi-
neering [31]. Therefore, we measured the number of cir-
culating HPCs using a standardized assay kit. A
comparative study that measures the number of circulat-
ing EPCs using a standardized definition must be investi-
gated in the future.
Vascular endothelial dysfunction contributes to the
initiation and progression of arteriosclerosis and serves as
a strong predictor of cardiovascular events [32,33]. We
previously reported that slight elevations of glucose and
insulin levels after 75 g OGTT are associated with the
severity of CAD even in patients with normal glucose
tolerance [3]. Ceriello et al. recently demonstrated that
oscillating glucose levels have more deleterious effects
than constant high glucose on endothelial function in dia-
betic patients [34]. We also reported that postprandial
hyperglycemia as well as hyperlipidemia induces endothe-
lial dysfunction [35]. In addition, improvement of post-
prandial hyperglycemia by a-glucosidase inhibitors
prevents endothelial dysfunction in diabetic patients with
CAD [35]. In the present study, no significant differences
in endothelial function as assessed by the PAT ratio were
observed after administration of the two drugs. Although
the number of circulating HPCs was significantly
increased after azelnidipine treatment, much longer time
might be needed to improve endothelial dysfunction in
this study population. Another possibility is the timing of
endothelial function assessment. The changes in endothe-
lial function at fasting may be relatively small compared
with the changes in postprandial values [35,36]. Several
non-invasive methods have been developed to measure
Table 4 Comparison of laboratory data and PAT ratio between treatment with azelnidipine and amlodipine
Baseline Azelnidipine
N=1 7
Amlodipine
N=1 7
P **
TC, mg/dL 191 ± 17 194 ± 22 191 ± 23 0.617
LDL-C, mg/L 109 ± 19 111 ± 24 110 ± 19 0.730
HDL-C, mg/dL 57 ± 17 58 ± 18 57 ± 17 0.437
Triglyceride, mg/dL 104 ± 60 110 ± 57 114 ± 65 0.750
HbA1c, % 5.1 ± 0.3 5.1 ± 0.2 5.1 ± 0.3 0.999
hs-CRP, mg/L 1.14 ± 2.66 0.36 ± 0.23 0.74 ± 0.76 0.067
Interleukin-6, pg/mL 1.31 ± 0.61 1.44 ± 0.73 1.81 ± 0.77 0.035
eGFR, ml/min/1.73 m
2 83.2 ± 18.3 82.3 ± 16.1 79.4 ± 15.8 0.188
L-FABP/U-Cr, ng/g Cr 29.4 ± 40.0 13.9 ± 16.2 17.9 ± 16.9 0.187
Micro-alb/U-Cr, mg/g Cr 23.6 ± 47.4 26.6 ± 59.9 38.0 ± 87.4 0.120
HPC,/μL 2.79 ± 1.67 3.56 ± 1.59* 2.65 ± 1.17 0.016
PAT ratio 1.93 ± 0.34 2.05 ± 0.39 2.11 ± 0.47 0.587
Data are mean ± SD. TC; total cholesterol, LDL-C; low-density lipoprotein cholesterol, HDL-C; high-density lipoprotein cholesterol, Hb; hemoglobin, hs-CRP; high
sensitivity C-reactive protein, BNP; brain natriuretic peptide, eGFR; estimated glomerular filtration ratio, GFR(ml/min/1.73 m
2) L-FABP, L-type fatty acid binding
protein, alb; albuminuria, U-Cre; urine creatinine, HPC; hematopoietic progenitor cell, PAT: peripheral arterial tonometry. * P < 0.05 vs. baseline. ** azelnidipine vs.
amlodipine.
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devices to assess endothelial function [19]. Further studies
are needed to elucidate the association between endothe-
lial function and differences in CCBs in the next step.
There were several potential limitations in the present
study. First, the sample sized was small. We conducted a
randomized crossover study. Therefore, we believe that
the differences between azelnidipine and amlodipine are
reliable. Second, we assessed the effects of administration
of each CCB for 12 weeks. Investigation of the impact of
long-term effects, including postprandial parameters and
clinical outcomes, is needed in the future. Third, as
described above, the mechanisms by which azelnidipine
ameliorated glucose tolerance after 75 g OGTT in non-
diabetic patients with hypertension, has not been clearly
elucidated. Fourth, we demonstrated the data of the PAT
ratio in endothelial function analyse, but several para-
meters can be used to assess endothelial function. Fifth,
the reproducibility of 75 g OGTT may require further
examinations. However, all testing procedures were per-
formed under the same conditions, including those of the
start time, room temperature, and quite waiting place.
Conclusions
These results suggest that azelnidipine treatment may have
beneficial effects against glucose intolerance, insulin sensi-
tivity, the inflammatory state, and circulating numbers of
progenitor cells in non-diabetic patients with essential
hypertension. Further prospective investigations in a large
population are required to confirm these findings.
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